- Sponsored Content
HCP Analysis by ELISA and Orthogonal Methods in Vaccine and Gene Therapy Development
June 21, 2021
20 Min View
Date: Jun 21, 2021
Duration: 20 Min
Sponsored by Cygnus Technologies
This webcast features: Jared Isaac, PhD, Sr. Scientist, Chromatography and Mass Spectrometry, Cygnus Technologies
Next-generation recombinant vaccines and gene therapy products require clinical and commercial manufacturing of protein antigens or viral vectors produced using cell culture technologies. Regulatory guidelines require testing for cell substrate related impurities, media and purification additives, as well as adventitious agents throughout vaccine and gene therapy development to study the candidate’s purity, safety, and efficacy. While low levels of most impurities can be inconsequential, patient safety demands that host cell proteins (HCPs) be eliminated or reduced to the lowest levels practical. A key step in downstream purification of viral vectors and recombinant vaccines is the selection of a platform HCP enzyme-linked immunosorbent assay (ELISA) kit or developing a custom HCP ELISA. One part of determining that the ELISA is fit for purpose is performing antibody coverage analysis.
In this webinar, we will discuss orthogonal Antibody Affinity Extraction and Mass Spectrometry methods used to assess ELISA Ab coverage to HCPs present in a process and identify process-specific HCPs that may copurify with a drug substance. Case studies of HEK 293, Sf9, and Vero cell-based processes will be presented.
This webcast is no longer available.
Andelyn to make viral vectors in FDA-NIH led gene therapy consortiumMar 1, 2024|1 Min Read
GLP-1 drug demand drives $250m fill/finish expansion for SimtraMar 1, 2024|3 Min Read
AstraZeneca to build global strategic center in ShanghaiMar 1, 2024|3 Min Read
Ins & Outs: Gonzalez but not forgotten at AbbVieFeb 29, 2024|2 Min Read
Mar 11 - Mar 14, 2024
Mar 11 - Mar 14, 2024
Accelerate speed to market for your next generation mAbs, vaccines, cell therapy, and gene therapy products. At the BioProcess International US West event in San Diego, CA, in March 2024 you can access today's innovative strategies and technologies designed to improve process efficiencies and maintain product quality across all phases of bioprocessing.Agenda